Jacobio Pharmaceuticals Group Co., Ltd.
HKEX:1167.HK
1.8 (HKD) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Jacobio Pharmaceuticals Group Co., Ltd. |
Symbool | 1167.HK |
Munteenheid | HKD |
Prijs | 1.82 |
Beurswaarde | 1,436,744,036 |
Dividendpercentage | 0% |
52-weken bereik | 1.38 - 4.57 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yinxiang Wang |
Website | https://www.jacobiopharma.com |
An error occurred while fetching data.
Over Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)